Xiapex (collagenase clostridium histolyticum), a non-surgical treatment for Dupuytren’s contracture in adult patients with a palpable cord, has been granted marketing authorization by the European Commission and should available for use in some European markets later this year. 

It is the first injectable treatment to be approved in the EU for the treatment of Dupuytren's contracture. Pfizer has the marketing rights to collagenase clostridium histolyticum in Europe, and Auxilium Pharmaceuticals has the rights in the rest of the world.